Psychiatr. pro Praxi, 2005; 5: 252-253

Jak ovlivňuje léčba antipsychotiky morfologii mozku?

MUDr. Martin Anders Ph.D
Psychiatrická klinika 1. LF UK a VFN Praha

S rozvojem zobrazovacích metod bylo zjištěno, že průběh schizofrenie je spojen s morfologickými změnami mozkové tkáně. Nejtypičtějším nálezem je úbytek objemu šedé hmoty, ale i celého mozku. Z klinického pohledu je nejvýznamnějším objevem rozdíl mezi tím, jak tento marker onemocnění ovlivňuje haloperidol a jak olanzapin. Z hodnocení výsledků prozatím unikátní studie vyplývá, že u léčených haloperidolem došlo k signifikantnímu úbytku objemu šedé hmoty, zatímco léčba olanzapinem podobnému jevu zabránila. Současně se podařilo opět prokázat, že haloperidol zvětšuje objem bazálních ganglií. Diskutován je mechanizmus neuroprotektivního účinku a význam těchto nálezů z pohledu klinické praxe.

Published: February 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Anders M. Jak ovlivňuje léčba antipsychotiky morfologii mozku? Psychiatr. praxi. 2005;9(5):252-253.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Arnold SE, Franz BR, Gur RC, et al. Smaller neuron size in schizophrenia in hippocampal subfields that mediate cortical-hippocampal interactions. Am J Psychiatry. 1995; 152: 738-748. Go to original source... Go to PubMed...
    2. DeLisi LE, Sakuma M, Tew W, Kushner M, Hoff A, Grimson R. Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatry Res. 1997; 74: 129-140. Go to original source... Go to PubMed...
    3. Falkai P, Honer WG, David S, Bogerts B, Majtenyi C, Bayer TA. No evidence for astrogliosis in brains of schizophrenic patients. A post-mortem study. Neuropathol Appl Neurobiol. 1999; 25: 48-53. Go to original source... Go to PubMed...
    4. Job DE, Whalley HC, McConnell S, Glabus M, Johnstone EC, Lawrie SM. Structural gray matter differences between first-episode schizophrenics and normal controls using voxel-based morphometry. Neuroimage. 2002; 17: 880-889. Go to original source... Go to PubMed...
    5. Johnstone EC, Crow TJ, Frith DC, Husband J, Krel L. Cerebral ventricular size and cognitive impairment in schizophrenia. Lancet. 1976; 2: 924-926. Go to original source... Go to PubMed...
    6. Johnstone EC, Abukmeil SS, Byrne M, et al. Edinburgh high risk study - findings after four years. Demographic, attainment and psychopathological issues. Schizophr Res. 2000; 46: 1-15. Go to original source... Go to PubMed...
    7. Konradi Ch, Heckers S. Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia. Biological Psychiatry, 2001; 50(10): 729-742. Go to original source... Go to PubMed...
    8. Lawrie SM, Abukmeil SS. Brain abnormality in schizophrenia: a systematic and quantitative review of volumetric magnetic resonance imaging studies. Br J Psychiatry. 1998; 172: 110-120. Go to original source... Go to PubMed...
    9. Lieberman JA et al. Antipsychotic Drug Effects on Brain Morphology in First-Episode Psychosis. Arch Gen Psychiatry. 2005; 62: 361-370. Go to original source... Go to PubMed...
    10. Pakkenberg B. Total nerve cell number of neocortex in chronic schizophrenics and controls estimated using optical dissectors. Biol Psychiatry. 1993; 34: 768-772. Go to original source... Go to PubMed...
    11. Staal WG, Hulshoff Pol HE, Schnack HG, van Haren NE, Seifert N, Kahn RS. Structural brain abnormalities in chronic schizophrenia at the extremes of the outcome spectrum. Am J Psychiatry. 2001; 158: 1140-1142. Go to original source... Go to PubMed...
    12. Suddath RL, Christison GW, Torrey EF, Casanova MF, Weinberger DR. Anatomical abnormalities in the brains of monozygotic twins discordant for schizophrenia [erratum appears in N Engl J Med 1990 May 31; 322(22): 1616]. N Engl J Med. 1990; 322: 789-794. Go to original source... Go to PubMed...
    13. Wright IC, Rabe-Hesketh S, Woodruff PWR, David AS, Murray RM, Bullmore ET. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry. 2000; 157: 16-25. Go to original source... Go to PubMed...
    14. Zipursky RB, Lim KO, Sullivan EV, Brown BW, Pfefferbaum A. Widespread cerebral gray matter volume deficits in schizophrenia. Arch Gen Psychiatry. 1992; 49: 195-205. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.